Natera (NASDAQ:NTRA) Stock: Insider Steven Leonard Chapman Sells 2,264 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 2,264 shares of the business’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $406.00, for a total transaction of $919,184.00. Following the transaction, the chief executive officer owned 94,662 shares in the company, valued at $38,432,772. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $1,462,346.20.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The stock was sold at an average price of $413.31, for a total transaction of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64.

Natera Stock Down 5.0%

NTRA stock opened at $414.30 on Friday. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The company has a 50-day moving average price of $377.06 and a 200 day moving average price of $266.44.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.74) EPS. As a group, research analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Large investors have recently added to or reduced their stakes in the stock. Provenance Wealth Advisors LLC purchased a new position in shares of Natera during the third quarter worth approximately $89,000. Factory Mutual Insurance Co. bought a new stake in shares of Natera during the third quarter valued at approximately $491,000. Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in shares of Natera in the third quarter valued at approximately $6,620,000. Greenleaf Trust purchased a new stake in shares of Natera in the third quarter valued at approximately $240,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Natera in the third quarter valued at approximately $7,545,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NTRA shares. Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Natera in a report on Monday, July 6th. Rothschild & Co Redburn assumed coverage on Natera in a report on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective for the company. Robert W. Baird set a $348.00 price objective on Natera in a research report on Friday, August 7th. Piper Sandler upped their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $394.31.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.